B7-H3/CD276: An Emerging Cancer Immunotherapy

Immunotherapy aiming at suppressing tumor development by relying on modifying or strengthening the immune system prevails among cancer treatments and points out a new direction for cancer therapy. B7 homolog 3 protein (B7-H3, also known as CD276), a newly identified immunoregulatory protein member o...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 12; p. 701006
Main Authors Zhou, Wu-Tong, Jin, Wei-Lin
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 19.07.2021
Subjects
Animals
B7 Antigens
B7-H3/CD276
cancer immunotherapy
Humans
immune checkpoint
Immunology
Immunotherapy - methods
Neoplasms
tumor immunology
Tumor Microenvironment
tumor immunology
tumor microenvironment
B7-H3/CD276
cancer immunotherapy
immune checkpoint
Online AccessGet full text

Cover

More Information
Summary:Immunotherapy aiming at suppressing tumor development by relying on modifying or strengthening the immune system prevails among cancer treatments and points out a new direction for cancer therapy. B7 homolog 3 protein (B7-H3, also known as CD276), a newly identified immunoregulatory protein member of the B7 family, is an attractive and promising target for cancer immunotherapy because it is overexpressed in tumor tissues while showing limited expression in normal tissues and participating in tumor microenvironment (TME) shaping and development. Thus far, numerous B7-H3-based immunotherapy strategies have demonstrated potent antitumor activity and acceptable safety profiles in preclinical models. Herein, we present the expression and biological function of B7-H3 in distinct cancer and normal cells, as well as B7-H3-mediated signal pathways in cancer cells and B7-H3-based tumor immunotherapy strategies. This review provides a comprehensive overview that encompasses B7-H3’s role in TME to its potential as a target in cancer immunotherapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Reviewed by: Wenping Ma, Capital Medical University, China; Lisa Sevenich, Georg Speyer Haus, Germany
Edited by: Mingzhu Yin, Central South University, China
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2021.701006